The role of PSA in the radiotherapy of prostate cancer

ONCOLOGY

Volumn 10, Issue 8, 1996, Pages 1143-1153

  Roach III, Mack ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROSTATE SPECIFIC ANTIGEN;

BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; FORECASTING; HUMAN; MALE; METHODOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATE TUMOR; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; FORECASTING; HUMANS; MALE; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0030204117     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Oesterling JE, Jacobsen SJ, Guess HA, et al: Longitudinal changes in serum PSA (PSA velocity) in a community-based cohort of men. Proc Am Urol Assoc 153:419A, 1995.
2. Partin AW, Kelly CA, Subong ENP. et al: Measurement of the ratio of free PSA to total PSA improves prostate cancer detection for men with total PSA levels between 4.0 and 10.0 ng/mL. Proc Am Urol Assoc 153:295A, 1995.
3. Catalona WJ, Smith DS, Wolfert RL, et al: Increased specificity of PSA screening through measurement of percent free PSA in serum. Proc Am Urol Assoc 153:312A, 1995.
4. Chan DW, Bruzek DJ, Oesterling JE, et al: Prostate-specific antigen as a marker for prostatic cancer: A monoclonal and a polyclonal immunoassay compared. Clin Chem 33:1916-1920. 1987.
5. Hortin GL, Bahnson RR, Daft M, et al: Differences in values obtained with 2 assays of prostate specific antigen. J Urol 139:762-765. 1988.
6. Mettlin C, Littrup PJ, Kane RA, et al: Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with agereferenced PSA, PSA density, and PSA change. Cancer 74:1615-1620, 1994.
7. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men. JAMA 270:860-864, 1993.
8. Vijayakumar V, Vijayakumar S, Quadri SF, et al: Can prostate specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Am J Clin Oncol 17(5):432-436, 1994.
9. Soble JJ, Basler W: Alkaline phosphatase. An effective and cost controlling determinant in prostate cancer staging. Proc Am Urol Assoc 153:354A, 1995.
10. Huncharek M, Muscat JK: Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. Cancer Invest 13:31-35, 1995.
11. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol 150:10-14, 1993.
12. Aihara M, Lebovitz RM, Wheeler TM, et al: Prostate specific antigen and gleason grade: An immunohistochemical study of prostate cancer. J Urol 151:1558-1564, 1994.
13. Littrup PJ, Kane RA, Mettlin CJ, et al: Cost-effective prostate cancer detection. Cancer 74:3146-3158, 1994
14. Lankford S, Pollack A, Zagars GK: PSA density as a prognostic factor in prostate cancer patients treated with radiotherapy, Int J Radiat Oncol Biol Phys 32:229, 1995.
15. Ingenito AC, Ennis RD, Hsu I-C, et al: Reexamining the role of prostate specific antigen density in predicting outcome for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32:231, 1995.
16. Hanlon AL, Hanks GE, Lee WR, et al: PSA doubling time is an independent predictor for outcome of prostate cancer treated by external beam radiation. Int J Radiat Oncol Biol Phys 32:231, 1995.
17. Roach M: RE: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:1923-1924, 1993.
18. Roach M, Marquez C, Yuo H, et al: Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33-37, 1993.
19. Diaz AZ, Roach M, Marquez C, et al: Indications for and significance of including the seminal vesicles during 3-D conformal radiotherapy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 30:323-329, 1994.
20. Chen A, Roach M, Diaz A, et al: Using pre-treatment PSA and Gleason score to predict for extra capsular extension among patients with clinically staged organ confined prostate cancer. Int J Radiat Oncol Biol Phys 32(suppl I):1020-1021, 1995.
21. Spevack L, Killion LT, West JC, et al: Predicting the patient at low risk for lymph node metastasis with localized prostate cancer: An analysis of four statistical models. Int J Radiat Oncol Biol Phys (in press).
22. Katcher J, Levin H, Zippe C, et al: Indications for seminal vesicle coverage in the treatment of clinically localized adenocarcinoma of the prostate with radiotherapy alone. Int J Radiat Oncol Biol Phys 32:234, 1995.
23. Partin AW, Yoo J, Carter HB, et al: RE: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:1924, 1993
24. Kaplan ID, Cox RS, Bagshaw MA: Prostate specific antigen after external beam radiotherapy for prostate cancer: Followup. J Urol 149:519-522, 1993.
25. Russell KJ, Dunatov C, Hafermann MD, et al: Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J Urol 146:1046-1052, 1991.
26. Hanks GE, Lee WR, Hanlon AL, et al: Conformal technique dose escalation in prostate cancer: improved cancer control with higher doses in patients with pretreatment PS A 10 ng/mL. Int J Radiat Oncol Biol Phys 32(suppl):141-142, 1995.
27. Zietman AL, Dallow KC, Shipley WU, et al: Time to second prostate specific antigen (PSA) failure is a surrogate endpoint for prostate cancer death in prospective trials of therapy for localized disease. Int J Radiat Oncol Biol Phys 32:229, 1995.
28. Zietman AL, Coen JJ, Dallow KC, et al: The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome. Int J Radiat Oncol Biol Phys 32(2):287-292, 1995.
29. Zagars GK: The prognostic significance of a single serum prostate-specific antigen value beyond six months after radiation therapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 27:39-45, 1993.
30. Roach M, Meehan S, Kroll S, et al: Radiotherapy for high-grade clinically localized adenocarcinoma of the prostate (submitted abstract). Proc Am Soc Clin Oncol, 1996.
31. Kuban DA, El-Mahdi AM, Schellhammer PF: Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer, Int J Radiat Oncol Biol Phys 32:307-316, 1995.
32. Adolfsson J, Carstensen J, Lowhagen T: Deferred treatment in clinically localized prostatic carcinoma. Br J Urol 69:187-187, 1992.
33. Crook JM, Perry GA, Robertson S, et al: Routine prostate biopsies following radiotherapy for prostate cancer: Results for 226 patients. Urology 45(4):624-632, 1995.
34. Dugan TC, Shipley WU, Young RH, et al: Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: Correlation with histological grade and current prostate specific antigen. J Urol 146:1313-1316, 1991.
35. Kuban DA, El-Mahdi AM, Schellhammer P: The significance of post-irradiation prostate biopsy with long-term follow-up, Int J Radiat Oncol Biol Phys 24:409-414, 1992.
36. Schellhammer PF, El-Mahdi EM, Schultheiss TE, et al: Prostate biopsy after definitive treatment by interstitial 125-iodine implant or external beam radiation therapy. J Urol 137:987, 1987.
37. Geist RW: Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate. Urology 45(6):1016-1021, 1995.
38. Hanks GE, Perez CA, Kozar M, et al: PSA confirmation of cure at 10 years of T1b, T2, NO, MO prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys 30:289-292, 1994.
39. Willett CG, Zietman AL, Shipley WU, et al: The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol 151:1579-1581, 1994.
40. Zelefsky MJ, Leibel SA, Wallner KE, et al: Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostate cancer. J Clin Oncol 13(2):459-463, 1995.
41. Kavadi VS, Zagars GK, Pollack A: Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications. Int J Radiat Oncol Biol Phys 30(2):279-287, 1994.
42. Critz FA, Tarlton RS, Holladay DA: Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. Cancer 75:2383-2391, 1995.
43. Tibbs MK, Zietman AL, Dallow KC, et al: Biochemical outcome following external beam radiation for T1-2 prostate carcinoma: The importance of achieving an undetectable nadir PSA. Int J Radiat Oncol Bio Phys 32(suppl 1):230, 1995.
44. Horwitz E, Ziaja E, Vicini F, et al: Assessing the variability of outcome for patients with localized prostate irradiation using different definitions of biochemical failure. Int J Radiat Oncol Biol Phys 32(suppl 1):228, 1995.
45. Sartor CI, Strawderman MH, Lin X, et al: Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 32:233, 1995.
46. Pilepich MV, Krall JM, Al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623, 1995.
47. Pollack A, Zagars GK, Kopplin S: Radiotherapy and androgen ablation for clinically localized high risk prostate cancer. Int J Radiat Oncol Biol Phys 32:13-20, 1995.
48. Catalona WJ, Smith DS: 5-Year tumor recurrence rates after anatomical radical prostatectomy for prostate cancer. J Urol 152:1837-1842, 1994.
49. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 152:1826-1830, 1994.
50. Partin AW, Pound CR, Clemens JQ, et al: Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 20(4):713-725, 1993.
51. Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (staged T2c or lower) prostate cancer. J Urol 152:1850-1857, 1994.
52. Yu H, Diamandis EP, Prestigiacomo AF, et al: Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem 41:430-434, 1995.
53. Partin AW, Pearson JD, Landis PK, et al: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43(5):649-659, 1994.
54. Roach M, Walner K: Prostate cancer, in Leibel S, Phillips TL (eds): The Textbook of Radiation Oncology, ch 22. New York, WB Saunders, 1996 (in press).
55. Katz AE, Olsson CA, Raffo AJ, et al: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43(6):765-775, 1994.